REGN7999 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-03 in 4mo
ESTIMATED |
READOUT
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999,
Phase 2 · Non-Transfusion Dependent Beta-Thalassemia (NTDT) |
REGN REGENERON PHARMACEUTICALS, I | REGN7999 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|